Articles
Breast cancer vaccine completes preclinical proof-of-concept study
Breast cancer vaccine candidate OQR200, developed by OncoQR, has successfully completed a proof-of-concept study in non-human primates (NHPs).
[ + ]Phosphagenics restructure effective immediately
Drug delivery company Phosphagenics has announced a corporate restructure, effective immediately, following its recent strategic review. [ + ]
Why don't elephants get cancer?
US researchers may have solved an intriguing mystery — why do elephants rarely get cancer? [ + ]
Gene variant increases depression risk for abused children
Scientists have produced further evidence linking a particular variant of the brain's serotonin transporter (SERT) gene to an increased risk of severe depression in individuals who suffered abuse as children. [ + ]
Automated plate assessment system exceeds expectations
Shares in LBT Innovations rose almost 20% as the medical technology company received successful results from a clinical trial of its culture plate analysis technology. [ + ]
The risky business of cell culture
The process of cell culture is one which can be beneficial for modelling health and disease but is not without its risks — risks which many scientists are often willing to take.
[ + ]Paranta Biosciences commences cystic fibrosis trial
Paranta Biosciences has successfully closed a $7 million financing round, which it will use to fund the development of treatments for inflammatory and fibrotic lung diseases. [ + ]
Laboratory market transformation drives systems innovation
The fast-changing laboratory market is ripe for a new generation of information systems that meet the needs of a modern pathology environment.
[ + ]The bubonic plague — 20 million years in the making?
Entomology researcher George Poinar, Jr has unearthed what he believes is a 20-million-year-old strain of the bubonic plague.
[ + ]US$53.9m for Avita to support mass burn injuries
Avita Medical has been awarded a contract with BARDA, worth up to $53.9 million, which supports late-stage clinical development and procurement of Avita's ReCell autologous cell harvesting device under a mass casualty preparedness program. [ + ]
Trialled in the wild — the Tasmanian devil vaccine
Nineteen Tasmanian devils, who were recently immunised against the deadly devil facial tumour disease (DFTD), have been released into Narawntapu National Park as part of a program to test the vaccine in the wild for the very first time. [ + ]
No snow-white apple fairytale for Australia
A Canadian company has begun marketing two non-browning apple varieties that employ CSIRO's patented gene-silencing technology. But in GM-averse Australia, there are no takers — why? [ + ]
The Daraprim price hike and the TPP
After a tumultuous week for Turing Pharmaceuticals — which saw the company raise the price of an essential medicine by over 4000%, only to lower it again in the face of universal criticism — an Australian intellectual property expert warns that similar incidents could occur as a result of the Trans-Pacific Partnership (TPP).
[ + ]Diamond defects produce bright fluorescence
Japanese researchers have discovered that germanium defects in a diamond crystal lattice act as a reliable source for single photons, providing a promising new route to building components for quantum cryptography and biomarkers. [ + ]
Australia's 3D-printed ribs
Australia has contributed to an international collaboration that has led to a world-first in surgery — the implantation of a 3D-printed titanium sternum and rib cage into a Spanish cancer patient. [ + ]
